Novartis appoints leaders for two new business units
Paul Hudson will be appointed CEO, Novartis Pharmaceuticals.
Mr. Hudson, currently Executive Vice President, North America and member of the Executive Committee, AstraZeneca, will join Novartis and lead Novartis Pharmaceuticals.
Prior to his role in North America, Mr. Hudson served as the leader of AstraZeneca's Japanese business. Novartis Pharmaceuticals will include the franchises Neuroscience, Ophthalmology, Immunology and Dermatology, Respiratory, Cardio-Metabolic and Established Medicines.
Mr. Hudson has broad pharmaceutical industry experience and in particular in cardiovascular and immunology, which complement Novartis' major product launches.
Bruno Strigini will become CEO, Novartis Oncology.
Mr. Strigini, currently Head of Novartis Oncology, will lead the Novartis Oncology business unit, comprised of the franchises Oncology and Cell and Gene Therapies.
Mr. Strigini joined Novartis in 2014 from Merck & Co. to lead the oncology business and was instrumental in the successful integration of the oncology assets acquired from GSK.
David Epstein, currently Division Head and CEO of Novartis Pharmaceuticals, has decided to leave Novartis and explore new challenges from the US.